| Gene symbol | PTGS2 | Synonyms | COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2, hCox-2 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1q31.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | prostaglandin-endoperoxide synthase 2 | ||||
| Gene symbol | TGFB1 | Synonyms | CED, DPD1, IBDIMDE, LAP, TGF-beta1, TGFB, TGFbeta | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | transforming growth factor beta 1 | ||||
| GTO ID | GTC2979 |
| Trial ID | NCT05309915 |
| Disease | Solid Tumor |
| Altered gene | TGFB1|PTGS2 |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | STP707 |
| Co-treatment | placebo |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 1, Single-Center, Randomized, Dose-Escalation, Sequential Cohort Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Dose of STP707 Administered Intravenously in Healthy Subjects |
| Year | 2022 |
| Country | United States |
| Company sponsor | Sirnaomics |
| Other ID(s) | SRN-707-002 |
| Vector information | |||
|
|||
| Cohort1: STP707_dose level 1 | |||||||
|
|||||||
| Cohort2: STP707_dose level 2 | |||||||
|
|||||||
| Cohort3: STP707_dose level 3 | |||||||
|
|||||||
| Cohort4: STP707_dose level 4 | |||||||
|
|||||||